Accessibility Statement

Business Ethics

Management Approach

At Lilly, we are committed to upholding high standards of corporate conduct in our business dealings around the world. Our code of business conduct – called The Red Book – and our policies, compliance management systems, HR performance and promotion systems, training programs and communications initiatives are designed to work together to reinforce a culture of integrity and ethical behavior.

As part of our commitment to operating ethically and responsibly, we have and continue to improve our ethics and compliance program. The program is designed to promote ethical conduct and instill a culture of integrity. We have dedicated individuals and teams within the ethics and compliance organization supporting global anti-corruption, bioethics, business continuity, enterprise risk management and privacy programs, as well as the fundamental elements of board-level oversight, written standards, education and training initiatives, and communications. Our program also includes monitoring, auditing and response to potential violations.

A key component to our culture of ethics and integrity is transparency around how we work. Lilly collaborates with health care professionals and organizations focusing on improving the health and quality of patients’ lives. We believe being transparent about our relationships with these external groups, advocacy organizations and other stakeholders helps Lilly build trust and respect for how we work with others to benefit the people we serve.

Ethics and Compliance

Our comprehensive approach to ethics and compliance includes proactive risk assessments, trainings and communications designed to prevent fraud or other violations of Lilly’s policies, as well as reporting, auditing and monitoring to detect potential compliance gaps. We assess risks in our business functions and the geographies where we operate to help business leaders understand, prioritize and mitigate risks related to ethics, compliance and fraud. We have a robust investigation process, and we develop corrective and preventive action plans to address issues as appropriate. We also use available data to improve our programs to help leaders assess the risks they face.

The Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer oversees this work and is responsible for developing and operating our ethics and compliance program, managing a diverse organization that works across the business. This individual reports to the CEO and provides regular updates to the Ethics and Compliance Committee of the Board of Directors, and each year the Board of Directors reviews the company’s prioritized enterprise risks, their associated mitigation plans and the company’s overall state of compliance. To provide a comprehensive review, the overall state of compliance report blends key information from various groups within Lilly, including corporate audit services, ethics and compliance, health, safety, and environment, and global quality.

Enterprise Risk Management Framework

Our Code of Business Conduct, Policies & Procedures

Our code of business conduct, policies and procedures are designed to reinforce our core values and provide guidance on how we expect business to be conducted. They include processes for interacting with health care providers, government officials and others, and they are designed to be consistent with codes issued by other relevant organizations, including the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industry Associations (EFPIA), and the Japan Pharmaceutical Manufacturers Association (JPMA).

Our global procedures and processes support the ethical marketing and promotion of our products and require the review and approval of this content by relevant subject matter experts. We investigate potential violations of these procedures and, as warranted, take corrective and preventive actions including reporting to regulatory authorities as appropriate.

In 2019 and 2020, we received no warning letters or untitled letters from the Office of Prescription Drug Promotion (OPDP), US Food and Drug Administration (US FDA) Center for Drug Evaluation and Research (CDER) or the Advertising and Promotional Labeling Branch (APLB) US FDA Center for Biologics Evaluation and Research. We received one untitled letter from OPDP in 2021 regarding a product campaign and one in 2022 regarding a social media post. Lilly applied the learnings from these untitled letters to its review processes for future communications involving all marketed products.

We regularly update and disseminate our compliance-related expectations through The Red Book, our code of business conduct. Available in 20 languages, this document and associated trainings are designed to support a judgment-based approach emphasizing the company’s values and the importance of ethical decision-making. The code of business conduct and associated training includes our 11 corporate policies:

  • Our Ethical Foundation

  • Conducting Research and Development

  • Respecting People

  • Assuring Quality

  • Ethical Interactions: Communicating Honestly

  • Ethical Interactions: Preventing Corruption

  • Maintaining Financial Integrity

  • Respecting Personal Information and Privacy

  • Managing and Protecting Information

  • Protecting People, the Environment and Our Assets

  • Speaking Up: No Retaliation

Anti-Corruption Compliance

Lilly’s commitment to operating with high ethical standards includes complying with applicable anti-bribery and anti-corruption (ABAC) laws and regulations, and it extends to business relationships, dealings and activities all over the world. Our global policies prohibit bribery, fraud and other acts of dishonesty, including that we do not offer, provide, authorize or accept anything of value – or give the appearance that we do – to inappropriately influence a decision or gain an unfair advantage. This also extends to our work with third parties. We use a risk-based anti-corruption due diligence process to evaluate certain third parties, as appropriate, before engaging them, including the following:

  • third parties who may be authorized by Lilly to interact with health care providers or government officials on the company’s behalf

  • prospective recipients of grants and donations

  • prospective business development partners.

When appropriate, as determined through our risk evaluation process, third parties are required to follow anti-corruption policy and procedure requirements and participate in anti-corruption training. As part of our ongoing monitoring efforts, we conduct independent Anti-Bribery Anti-Corruption (ABAC) assessments of certain third parties, which often includes site visits and transaction testing. We also conduct an annual global anti-corruption risk assessment to identify potential risks and develop appropriate risk mitigation plans.

In addition, employees who are in positions most likely to interact with third parties are required to complete additional scenario-based training above and beyond our code of business conduct training each year. This training, which includes anti-corruption training, is designed to reinforce our policies, procedures and processes that promote ethical interactions. In 2022, more than 99% of required employees completed this additional training. Employees who do not complete required ethics and compliance training receive HR discipline as appropriate.

Respecting Privacy

Privacy is a top priority for Lilly, as reflected by our longstanding global privacy program. At its core, our privacy program reflects our commitment to being open and honest about how we collect, manage, use and disclose personal information. We are intentional about protecting personal information and strive to use the minimum amount necessary to do our work. We share personal information only with those who are authorized and have a legitimate business need to see it, and we insist our suppliers and third parties handle personal information in accordance with core privacy expectations, as well as applicable laws and regulations.

At Lilly, we expect our employees, suppliers and anyone working on our behalf to work responsibly and protect the personal information that is entrusted to us. These expectations are stated in our global Respecting Personal Information and Privacy policy, as well as our Respecting Privacy procedure, and are emphasized in enterprise-wide training on the responsible use of personal information.

Governance of Privacy

The Global Privacy Office oversees the privacy program for our operations around the world and is led by our Chief Privacy Officer, working with a team of global and local privacy experts. The Chief Privacy Officer reports directly to the Executive Vice President, Enterprise Risk Management and Chief Ethics and Compliance Officer, reflecting a governance structure emphasizing the importance of data privacy. As the volume of data grows exponentially and as comprehensive data privacy laws proliferate in the U.S. and worldwide, privacy has become a board-level priority. In addition to running its standard risk assessment process, the privacy team is actively engaged with relevant external constituents to stay abreast of new privacy laws, related risks and potential impacts of noncompliance, as appropriate, and to inform leadership of such developments as warranted. The privacy team also shares developing privacy requirements and identifies key privacy risks to our broader ethics and compliance organization, as well as to other key internal stakeholders, including our corporate audit team partners.


Our investment in bioethics capabilities reflects our company values and purpose to improve people’s lives and communities around the world. We were one of the first pharmaceutical companies to establish a standing bioethics committee in 1999. Our bioethics program is designed to address the increasingly complex and fast-paced ethical challenges of global pharmaceutical research, development and commercialization. Our focus is to protect and advocate for the rights and well-being of research participants and patients as well as the integrity of the scientific process and its applications for health care.

Our bioethics program provides Lilly employees with resources including the Lilly Bioethics Framework for Human Biomedical Research, position papers on major bioethical issues, information on how to request a bioethics consultation, and bioethics education and training opportunities. We also sponsor an annual bioethics lecture. Additionally, our staff and the Bioethics Advisory Committee provide input into policy decisions that have bioethical implications, and we collaborate externally to establish best practices in applying bioethics across the industry. In 2022, we shared information about our bioethics program at national and international bioethics meetings including the 16th World Congress of Bioethics and the Public Responsibility in Medicine and Research annual conference.

Governance of Bioethics

Our bioethics program reports into the Executive Vice President, Enterprise Risk Management and Chief Ethics and Compliance Officer, and works closely with the office of the Chief Medical Officer. Our bioethics staff, which has specialized training and expertise, provides education and training for the cross-functional Bioethics Advisory Committee, which includes external bioethics experts. This committee serves as a resource for Lilly employees and is a place where they can seek guidance on bioethics considerations, discuss potential alternative courses of action and receive recommendations on potential paths forward. Throughout these interactions, by applying the principles in the Lilly Bioethics Framework, bioethics contributes to our research study design, informed consent processes and content, selection of countries for clinical trial sites, requests for access to investigational treatments outside of clinical trials, animal care and use, engagement of special populations (e.g., pediatrics), as well as timing and content of research publications, among other matters.

Bioethics Program

Our bioethics program has four core activities: consultation, education and training, development of bioethics positions, and collaboration.

Our bioethics staff provides consultations for employees seeking advice regarding bioethics and research ethics issues. To increase workforce knowledge about bioethics, we have developed the Bioethics Leadership Academy (BELA) that provides a specialized curriculum in bioethics for Lilly employee development. Our Bioethics Framework for Human Biomedical Research and our Principles of Medical Research provide a bioethics foundation for the company’s positions on bioethics issues, promoting alignment with broadly accepted ethics principles and Lilly’s core values of integrity, excellence and respect for people. As an example of collaboration, in 2022 our bioethics team partnered with the advanced analytics and data sciences organization to devise a framework for the responsible development and application of artificial intelligence. Our bioethics program aims to work with other companies to establish best practices and to bring an industry perspective to bioethics discussions.

Protecting Research Subjects’ Rights in Clinical Trials

Our bioethics program advocates for the rights and well-being of research subjects and patients who use our medicines. Lilly applies a single global standard to the conduct of medical trials involving human subjects. This standard is based on well-respected ethics guidance and other requirements including:

Lilly conducts clinical studies in countries or communities in which the benefits of research can be made reasonably available for research participants and the host country or community. Sometimes an investigational medicine is not locally commercially available at the conclusion of a clinical study and as a result, clinical study patients who are benefiting from an investigational medicine are not able to access the treatment. Under certain conditions Lilly may offer continued access (otherwise known as post-trial access) to an investigational medicine after a patient's participation in a clinical study has ended.

Learn more about our approach to continued access to investigational medicine and multinational clinical studies.

Transparency, Disclosure and Political Engagement

We support various transparency initiatives globally, provided that such initiatives:

  • are respectful of local laws related to intellectual property, trade secrets, competition and privacy,

  • disclosure of information does not undermine our ability to compete effectively, and

  • information is communicated with appropriate context in an easily understood manner.

We seek to collaborate with policy makers, industry colleagues and key stakeholders to align on approaches that achieve these objectives.

Clinical Trials Data Transparency

Lilly is committed to the transparency of our clinical studies and we recognize that responsible sharing of clinical study data can enhance public health. Since 2014, Lilly has enhanced our transparency initiatives in alignment with the PhRMA/EFPIA Principles for Responsible Clinical Trial Data Sharing. Currently, Lilly registers and posts results of clinical trials on in addition to any legally required clinical trial registries. For Phase 2 and 3 trials that completed after 2019, Lilly submits results to one year after the completion of the trial regardless of the medicine’s approval status.

Lilly makes anonymized patient-level data available from Lilly-sponsored trials on marketed drugs for approved uses following acceptance for publication. Lilly is one of several companies that provide this access through the website Qualified researchers can submit research proposals and request anonymized data to test new hypotheses.

In 2013, Lilly began conducting pilot projects creating summaries of Phase 2 and 3 clinical trial results in patient-friendly language using simple, everyday terms. Since 2021, Lilly has created plain language summaries of Phase 2-4 clinical trial results in English.

Payments to Physicians and Healthcare Organizations

Read about our approach to payments to health care professionals and health care organizations.

Political and Policy Participation

Read about our disclosures on political and policy participation.

See important information about our ESG report.